LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 180

Search options

  1. Article ; Online: Responding to SARS-CoV-2 on College Campuses-Only Beginning to Understand What Works and Why.

    Paltiel, A David

    JAMA network open

    2021  Volume 4, Issue 12, Page(s) e2138904

    MeSH term(s) COVID-19 ; Educational Status ; Humans ; SARS-CoV-2 ; Universities
    Language English
    Publishing date 2021-12-01
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2021.38904
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021.

    Paltiel, A David / Schwartz, Jason L

    Annals of internal medicine

    2021  Volume 174, Issue 11, Page(s) 1563–1571

    Abstract: Background: Effective vaccines, improved testing technologies, and decreases in COVID-19 incidence prompt an examination of the choices available to residential college administrators seeking to safely resume in-person campus activities in fall 2021.: ...

    Abstract Background: Effective vaccines, improved testing technologies, and decreases in COVID-19 incidence prompt an examination of the choices available to residential college administrators seeking to safely resume in-person campus activities in fall 2021.
    Objective: To help college administrators design and evaluate customized COVID-19 safety plans.
    Design: Decision analysis using a compartmental epidemic model to optimize vaccination, testing, and other nonpharmaceutical interventions depending on decision makers' preferences, choices, and assumptions about epidemic severity and vaccine effectiveness against infection, transmission, and disease progression.
    Setting: U.S. residential colleges.
    Participants: Hypothetical cohort of 5000 persons (students, faculty, and staff) living and working in close proximity on campus.
    Measurements: Cumulative infections over a 120-day semester.
    Results: Under base-case assumptions, if 90% coverage can be attained with a vaccine that is 85% protective against infection and 25% protective against asymptomatic transmission, the model finds that campus activities can be resumed while holding cumulative cases below 5% of the population without the need for routine, asymptomatic testing. With 50% population coverage using such a vaccine, a similar cap on cumulative cases would require either daily asymptomatic testing of unvaccinated persons or a combination of less frequent testing and resumption of aggressive distancing and other nonpharmaceutical prevention policies. Colleges returning to pre-COVID-19 campus activities without either broad vaccination coverage or high-frequency testing put their campus population at risk for widespread viral transmission.
    Limitation: Uncertainty in data, particularly vaccine effectiveness (preventive and transmission); no distinguishing between students and employees; and assumes limited community intermixing.
    Conclusion: Vaccination coverage is the most powerful tool available to residential college administrators seeking to achieve a safe return to prepandemic operations this fall. Given the breadth of potential outcomes in the face of uncontrollable and uncertain factors, even colleges with high vaccination rates should be prepared to reinstitute or expand testing and distancing policies on short notice.
    Primary funding source: National Institute on Drug Abuse.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; Decision Support Techniques ; Disease Transmission, Infectious/prevention & control ; Humans ; Incidence ; Mass Screening ; Pandemics ; Risk Assessment ; SARS-CoV-2 ; United States/epidemiology ; Universities/organization & administration
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-08-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M21-2965
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP): Straight A's.

    Walensky, Rochelle P / Paltiel, A David

    JAMA network open

    2019  Volume 2, Issue 6, Page(s) e195042

    Language English
    Publishing date 2019-06-05
    Publishing country United States
    Document type Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2019.5042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Clinical and Economic Impact of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.

    Paltiel, A David / Zheng, Amy / Sax, Paul E

    medRxiv : the preprint server for health sciences

    2021  

    Abstract: Background: The value of frequent, rapid testing to reduce community transmission of SARS-CoV-2 is poorly understood.: Objective: To define performance standards and predict the clinical, epidemiological, and economic outcomes of nationwide, home- ... ...

    Abstract Background: The value of frequent, rapid testing to reduce community transmission of SARS-CoV-2 is poorly understood.
    Objective: To define performance standards and predict the clinical, epidemiological, and economic outcomes of nationwide, home-based, antigen testing.
    Design: A simple compartmental epidemic model estimated viral transmission, clinical history, and resource use, with and without testing.
    Data sources: Parameter values and ranges informed by Centers for Disease Control guidance and published literature.
    Target population: United States population.
    Time horizon: 60 days.
    Perspective: Societal. Costs include: testing, inpatient care, and lost workdays.
    Intervention: Home-based SARS-CoV-2 antigen testing.
    Outcome measures: Cumulative infections and deaths, numbers isolated and/or hospitalized, and total costs.
    Results of base-case analysis: Without a testing intervention, the model anticipates 15 million infections, 125,000 deaths, and $10.4 billion in costs ($6.5 billion inpatient; $3.9 billion lost productivity) over a 60-day horizon. Weekly availability of testing may avert 4 million infections and 19,000 deaths, raising costs by $21.5 billion. Lower inpatient outlays ($5.9 billion) would partially offset additional testing expenditures ($12.0 billion) and workdays lost ($13.9 billion), yielding incremental costs per infection (death) averted of $5,400 ($1,100,000).
    Results of sensitivity analysis: Outcome estimates vary widely under different behavioral assumptions and testing frequencies. However, key findings persist across all scenarios: large reductions in infections, mortality, and hospitalizations; and costs per death averted roughly an order of magnitude lower than commonly accepted willingness-to-pay values per statistical life saved ($5-17 million).
    Limitations: Analysis restricted to at-home testing and limited by uncertainties about test performance.
    Conclusion: High-frequency home testing for SARS-CoV-2 using an inexpensive, imperfect test could contribute to pandemic control at justifiable cost and warrants consideration as part of a national containment strategy.
    Language English
    Publishing date 2021-02-08
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2021.02.06.21251270
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis.

    Savinkina, Alexandra / Paltiel, A David / Ross, Joseph S / Gonsalves, Gregg

    Open forum infectious diseases

    2022  Volume 9, Issue 12, Page(s) ofac637

    Abstract: Background: New coronavirus disease 2019 (COVID-19) medications force decision-makers to weigh limited evidence of efficacy and cost in determining which patient populations to target for treatment. A case in point is nirmatrelvir/ritonavir, a drug that ...

    Abstract Background: New coronavirus disease 2019 (COVID-19) medications force decision-makers to weigh limited evidence of efficacy and cost in determining which patient populations to target for treatment. A case in point is nirmatrelvir/ritonavir, a drug that has been recommended for elderly, high-risk individuals, regardless of vaccination status, even though clinical trials have only evaluated it in unvaccinated patients. A simple optimization framework might inform a more reasoned approach to the trade-offs implicit in the treatment allocation decision.
    Methods: We conducted a cost-effectiveness analysis using a decision-analytic model comparing 5 nirmatrelvir/ritonavir prescription policy strategies, stratified by vaccination status and risk for severe disease. We considered treatment effectiveness at preventing hospitalization ranging from 21% to 89%. Sensitivity analyses were performed on major parameters of interest. A web-based tool was developed to permit decision-makers to tailor the analysis to their settings and priorities.
    Results: Providing nirmatrelvir/ritonavir to unvaccinated patients at high risk for severe disease was cost-saving when effectiveness against hospitalization exceeded 33% and cost-effective under all other data scenarios we considered. The cost-effectiveness of other allocation strategies, including those for vaccinated adults and those at lower risk for severe disease, depended on willingness-to-pay thresholds, treatment cost and effectiveness, and the likelihood of severe disease.
    Conclusions: Priority for nirmatrelvir/ritonavir treatment should be given to unvaccinated persons at high risk of severe disease from COVID-19. Further priority may be assigned by weighing treatment effectiveness, disease severity, drug cost, and willingness to pay for deaths averted.
    Language English
    Publishing date 2022-11-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofac637
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Planning for Mpox on a College Campus: A Model-Based Decision-Support Tool.

    Savinkina, Alexandra / Chitwood, Melanie / Kwon, Jiye / Pitzer, Virginia E / Gonsalves, Gregg / Paltiel, A David

    Annals of internal medicine

    2023  Volume 176, Issue 3, Page(s) 340–347

    Abstract: Background: In spring and summer 2022, an outbreak of mpox occurred worldwide, largely confined to men who have sex with men (MSM). There was concern that mpox could break swiftly into congregate settings and populations with high levels of regular ... ...

    Abstract Background: In spring and summer 2022, an outbreak of mpox occurred worldwide, largely confined to men who have sex with men (MSM). There was concern that mpox could break swiftly into congregate settings and populations with high levels of regular frequent physical contact, like university campus communities.
    Objective: To estimate the likelihood of an mpox outbreak and the potential effect of mitigation measures in a residential college setting.
    Design: A stochastic dynamic SEIR (susceptible, exposed but not infectious, infectious, or recovered) model of mpox transmission in a study population was developed, composed of: a high-risk group representative of the population of MSM with a basic reproductive number (
    Setting: U.S. residential college campus.
    Participants: Hypothetical cohort of 6500 students.
    Intervention: Isolation, quarantine, and vaccination of close contacts.
    Measurements: Proportion of 1000 simulations producing sustained transmission; mean cases given sustained transmission; maximum students isolated, quarantined, and vaccinated. All projections are estimated over a planning horizon of 100 days.
    Results: Without mitigation measures, the model estimated an 83% likelihood of sustained transmission, leading to an average of 183 cases. With detection and isolation of 20%, 50%, and 80% of cases, the average infections would fall to 117, 37, and 8, respectively. Reactive vaccination of contacts of detected cases (assuming 50% detection and isolation) reduced mean cases from 37 to 17, assuming 20 vaccinated contacts per detected case. Preemptive vaccination of 50% of the high-risk population before outbreak reduced cases from 37 to 14, assuming 50% detection and isolation.
    Limitation: A model is a stylized portrayal of behavior and transmission on a university campus.
    Conclusion: Based on our current understanding of mpox epidemiology among MSM in the United States, this model-based analysis suggests that future outbreaks of mpox on college campuses may be controlled with timely detection and isolation of symptomatic cases.
    Primary funding source: National Institutes of Health National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.
    MeSH term(s) Male ; Humans ; United States/epidemiology ; COVID-19 ; Homosexuality, Male ; Universities ; Mpox (monkeypox) ; Sexual and Gender Minorities
    Language English
    Publishing date 2023-01-31
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M22-2734
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.

    Paltiel, A David / Zheng, Amy / Schwartz, Jason L

    Annals of internal medicine

    2021  Volume 174, Issue 4, Page(s) 568–570

    MeSH term(s) COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; Communicable Disease Control/organization & administration ; Disease Progression ; Efficiency ; Humans ; Pandemics/prevention & control ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Time Factors ; United States/epidemiology ; United States Food and Drug Administration
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-01-05
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M20-7866
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.

    Paltiel, A David / Zheng, Amy / Sax, Paul E

    Annals of internal medicine

    2021  Volume 174, Issue 6, Page(s) 803–810

    Abstract: Background: The value of frequent, rapid testing to reduce community transmission of SARS-CoV-2 is poorly understood.: Objective: To define performance standards and predict the clinical, epidemiologic, and economic outcomes of nationwide, home-based ...

    Abstract Background: The value of frequent, rapid testing to reduce community transmission of SARS-CoV-2 is poorly understood.
    Objective: To define performance standards and predict the clinical, epidemiologic, and economic outcomes of nationwide, home-based antigen testing.
    Design: A simple compartmental epidemic model that estimated viral transmission, portrayed disease progression, and forecast resource use, with and without testing.
    Data sources: Parameter values and ranges as informed by Centers for Disease Control and Prevention guidance and published literature.
    Target population: U.S. population.
    Time horizon: 60 days.
    Perspective: Societal; costs included testing, inpatient care, and lost workdays.
    Intervention: Home-based SARS-CoV-2 antigen testing.
    Outcome measures: Cumulative infections and deaths, number of persons isolated and hospitalized, and total costs.
    Results of base-case analysis: Without a testing intervention, the model anticipates 11.6 million infections, 119 000 deaths, and $10.1 billion in costs ($6.5 billion in inpatient care and $3.5 billion in lost productivity) over a 60-day horizon. Weekly availability of testing would avert 2.8 million infections and 15 700 deaths, increasing costs by $22.3 billion. Lower inpatient outlays ($5.9 billion) would partially offset additional testing expenditures ($12.5 billion) and workdays lost ($14.0 billion), yielding incremental cost-effectiveness ratios of $7890 per infection averted and $1 430 000 per death averted.
    Results of sensitivity analysis: Outcome estimates vary widely under different behavioral assumptions and testing frequencies. However, key findings persist across all scenarios, with large reductions in infections, mortality, and hospitalizations. Costs per death averted are roughly an order of magnitude lower than commonly accepted willingness-to-pay values per statistical life saved ($5 to $17 million).
    Limitations: Analysis was restricted to at-home testing. There are uncertainties concerning test performance.
    Conclusion: High-frequency home testing for SARS-CoV-2 with an inexpensive, imperfect test could contribute to pandemic control at justifiable cost and warrants consideration as part of a national containment strategy.
    Primary funding source: National Institutes of Health.
    MeSH term(s) COVID-19/diagnosis ; COVID-19/mortality ; COVID-19/prevention & control ; COVID-19 Testing/economics ; Cost-Benefit Analysis ; Disease Progression ; Female ; Home Care Services/economics ; Humans ; Male ; Mass Screening/economics ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/mortality ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Sick Leave/economics ; United States/epidemiology
    Language English
    Publishing date 2021-03-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M21-0510
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Assessing COVID prevention strategies to permit the safe opening of college campuses in fall 2021

    Paltiel, A David / Schwartz, Jason L

    medRxiv

    Abstract: Background: Effective vaccines, improved testing technologies, and declines in COVID-19 incidence prompt an examination of the choices available to college administrators to safely resume in-person campus activities in fall 2021. Objective: To develop a ... ...

    Abstract Background: Effective vaccines, improved testing technologies, and declines in COVID-19 incidence prompt an examination of the choices available to college administrators to safely resume in-person campus activities in fall 2021. Objective: To develop a decision support tool that assists college administrators in designing and evaluating customized COVID vaccination, screening, and prevention plans. Design: Decision analysis linked to a compartmental epidemic model, quantifying the interaction of policy instruments (e.g., vaccination promotion, asymptomatic testing, physical distancing, and other non-pharmaceutical interventions), institutional priorities (e.g., risk tolerance, desire to resume activities), and assumptions about vaccine performance and background epidemic severity. Participants: Hypothetical cohort of 5000 individuals (students, faculty, and staff) living and working in the close environs of a residential college campus. Main Outcome(s) and Measure(s): Cumulative infections over a 120-day semester. Results: Under Base Case assumptions, if 90% coverage with an 85%-effective vaccine can be attained, the model finds that campus activities can be fully resumed while holding cumulative cases below 5% of the population without the need for routine, asymptomatic testing. With 50% population coverage using such a vaccine, a similar return to normalcy would require daily asymptomatic testing of unvaccinated individuals. The effectiveness of vaccination in reducing susceptibility to infection is a critical uncertainty. Conclusions & Relevance: Vaccination coverage is the most powerful tool available to college administrators to achieve a safe return to pre-pandemic operations this fall. Given the breadth of potential outcomes in the face of uncontrollable and uncertain factors, even colleges that achieve high vaccination coverage should be prepared to reinstitute testing and distancing policies on short notice.
    Keywords covid19
    Language English
    Publishing date 2021-07-22
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.07.19.21260522
    Database COVID19

    Kategorien

  10. Article ; Online: Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States.

    Paltiel, A David / Zheng, Amy / Walensky, Rochelle P

    JAMA network open

    2020  Volume 3, Issue 7, Page(s) e2016818

    Abstract: Importance: The coronavirus disease 2019 (COVID-19) pandemic poses an existential threat to many US residential colleges; either they open their doors to students in September or they risk serious financial consequences.: Objective: To define severe ... ...

    Abstract Importance: The coronavirus disease 2019 (COVID-19) pandemic poses an existential threat to many US residential colleges; either they open their doors to students in September or they risk serious financial consequences.
    Objective: To define severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) screening performance standards that would permit the safe return of students to US residential college campuses for the fall 2020 semester.
    Design, setting, and participants: This analytic modeling study included a hypothetical cohort of 4990 students without SARS-CoV-2 infection and 10 with undetected, asymptomatic SARS-CoV-2 infection at the start of the semester. The decision and cost-effectiveness analyses were linked to a compartmental epidemic model to evaluate symptom-based screening and tests of varying frequency (ie, every 1, 2, 3, and 7 days), sensitivity (ie, 70%-99%), specificity (ie, 98%-99.7%), and cost (ie, $10/test-$50/test). Reproductive numbers (Rt) were 1.5, 2.5, and 3.5, defining 3 epidemic scenarios, with additional infections imported via exogenous shocks. The model assumed a symptomatic case fatality risk of 0.05% and a 30% probability that infection would eventually lead to observable COVID-19-defining symptoms in the cohort. Model projections were for an 80-day, abbreviated fall 2020 semester. This study adhered to US government guidance for parameterization data.
    Main outcomes and measures: Cumulative tests, infections, and costs; daily isolation dormitory census; incremental cost-effectiveness; and budget impact.
    Results: At the start of the semester, the hypothetical cohort of 5000 students included 4990 (99.8%) with no SARS-CoV-2 infection and 10 (0.2%) with SARS-CoV-2 infection. Assuming an Rt of 2.5 and daily screening with 70% sensitivity, a test with 98% specificity yielded 162 cumulative student infections and a mean isolation dormitory daily census of 116, with 21 students (18%) with true-positive results. Screening every 2 days resulted in 243 cumulative infections and a mean daily isolation census of 76, with 28 students (37%) with true-positive results. Screening every 7 days resulted in 1840 cumulative infections and a mean daily isolation census of 121 students, with 108 students (90%) with true-positive results. Across all scenarios, test frequency was more strongly associated with cumulative infection than test sensitivity. This model did not identify symptom-based screening alone as sufficient to contain an outbreak under any of the scenarios we considered. Cost-effectiveness analysis selected screening with a test with 70% sensitivity every 2, 1, or 7 days as the preferred strategy for an Rt of 2.5, 3.5, or 1.5, respectively, implying screening costs of $470, $910, or $120, respectively, per student per semester.
    Conclusions and relevance: In this analytic modeling study, screening every 2 days using a rapid, inexpensive, and even poorly sensitive (>70%) test, coupled with strict behavioral interventions to keep Rt less than 2.5, is estimated to maintain a controllable number of COVID-19 infections and permit the safe return of students to campus.
    MeSH term(s) Basic Reproduction Number ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/transmission ; Cost-Benefit Analysis ; Disease Transmission, Infectious/prevention & control ; Humans ; Mass Screening/economics ; Pandemics ; Patient Isolation ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/transmission ; Risk Assessment/economics ; SARS-CoV-2 ; Sensitivity and Specificity ; United States/epidemiology ; Universities/economics ; Universities/organization & administration
    Keywords covid19
    Language English
    Publishing date 2020-07-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2020.16818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top